KDT-3594
/ Kissei, AffaMed Therap
- LARVOL DELTA
Home
Next
Prev
1 to 10
Of
10
Go to page
1
December 09, 2024
A Late Phase II Clinical Trial of KDT-3594 in Patients With Parkinson's Disease
(clinicaltrials.gov)
- P2 | N=150 | Recruiting | Sponsor: Kissei Pharmaceutical Co., Ltd.
Metastases • New P2 trial • CNS Disorders • Movement Disorders • Parkinson's Disease
May 11, 2022
A Clinical Study of KDT-3594 in Japanese Patients With Early Parkinson's Disease
(clinicaltrials.gov)
- P2 | N=7 | Completed | Sponsor: Kissei Pharmaceutical Co., Ltd. | Active, not recruiting ➔ Completed | Trial completion date: Mar 2022 ➔ Sep 2021 | Trial primary completion date: Mar 2022 ➔ Sep 2021
Trial completion • Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease
August 27, 2021
A Clinical Study of KDT-3594 in Japanese Patients With Early Parkinson's Disease
(clinicaltrials.gov)
- P2; N=6; Active, not recruiting; Sponsor: Kissei Pharmaceutical Co., Ltd.; Recruiting ➔ Active, not recruiting
Clinical • Enrollment closed • CNS Disorders • Movement Disorders • Parkinson's Disease
May 27, 2021
AffaMed Therapeutics Announces Approval for the Phase IIb Clinical Study of AM006 in China for the Treatment of Parkinson’s Disease
(PRNewswire)
- "AffaMed Therapeutics...today announced that China's National Medical Products Administration (NMPA) has approved the Clinical Trial Application (CTA) for a Phase IIb global clinical trial led by AffaMed to evaluate the safety and efficacy of AM006 in patients with early Parkinson's Disease (PD)...By 2030 however, China is expected to account for close to 50% of PD patients globally, illustrating the significant scale of treatment needs required to be met in the future."
New P2b trial • Non-US regulatory • CNS Disorders • Parkinson's Disease
April 30, 2021
A Clinical Study of KDT-3594 in Japanese Patients With Early Parkinson's Disease
(clinicaltrials.gov)
- P2; N=6; Recruiting; Sponsor: Kissei Pharmaceutical Co., Ltd.
Clinical • New P2 trial • CNS Disorders • Movement Disorders • Parkinson's Disease
February 17, 2021
A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.
(clinicaltrials.gov)
- P2; N=74; Completed; Sponsor: Kissei Pharmaceutical Co., Ltd.; Active, not recruiting ➔ Completed; Trial completion date: Jun 2020 ➔ Feb 2020; Trial primary completion date: Jun 2020 ➔ Feb 2020
Clinical • Trial completion • Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease
October 14, 2020
CBC-funded Affamed merges with Everinsight, extends portfolio with Kissei PD candidate
(Bioworld)
- Subscription needed.
Licensing / partnership • CNS Disorders • Parkinson's Disease
March 30, 2020
A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.
(clinicaltrials.gov)
- P2; N=100; Active, not recruiting; Sponsor: Kissei Pharmaceutical Co., Ltd.; Recruiting ➔ Active, not recruiting
Clinical • Enrollment closed
April 01, 2019
Clinical Study of KDT-3594 in Healthy Adult Males and Patients With Parkinson's Disease
(clinicaltrials.gov)
- P1; N=36; Completed; Sponsor: Kissei Pharmaceutical Co., Ltd.; Active, not recruiting ➔ Completed; Trial completion date: Jan 2019 ➔ Aug 2018; Trial primary completion date: Jan 2019 ➔ Aug 2018
Clinical • Trial completion • Trial completion date • Trial primary completion date
February 19, 2019
A Clinical Study of KDT-3594 in Patients With Early Parkinson's Disease.
(clinicaltrials.gov)
- P2; N=100; Recruiting; Sponsor: Kissei Pharmaceutical Co., Ltd.
Clinical • New P2 trial
1 to 10
Of
10
Go to page
1